Santen Holdings completed the acquisition of Eyevance Pharmaceuticals Holdings for $225m.

Santen Holdings, a wholly-owned subsidiary of Santen Pharmaceutical, a producer and distributor of ophthalmic medicine, completed the acquisition of Eyevance Pharmaceuticals, a pharmaceutical company, for $225m. "We're very pleased to have entered into this agreement. Through this purchase, we will quickly establish a business base in the U.S. and both humbly face and further contribute to the needs of a greater number of patients by offering more value. At the same time, we will accelerate global business rollout by gaining access to the U.S. and our presence in the market, aiming for even further corporate growth and contribution to ophthalmic treatments for people around the world.," Shigeo Taniuchi, Santen President and CEO.